 Midatech Pharma PLC AIM:MTPH is in demand after a positive European approval for a key product. The biotechnology company said that the European Medicines Agency had granted orphan medicinal product designation for its development programme of MTX110 for the treatment of glioma Midatech has been developing MTX110 for the treatment of recurrent glioblastoma rGBM in adult patients and diffuse intrinsic pontine glioma DIPG and medulloblastoma in paediatric patients. 